MoonLake Immunotherapeutics Investors Can Join Class Action Lawsuit Led by Schall Law Firm

Investors Encouraged to Join Class Action Against MoonLake Immunotherapeutics

The Schall Law Firm has issued a reminder for investors to consider joining a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX). This legal action centers around alleged violations of federal securities laws, specifically §10(b) and §20(a) of the Securities Exchange Act of 1934 along with Rule 10b-5. Investors who purchased shares of MoonLake between March 10, 2024, and September 29, 2025, are strongly encouraged to contact the Schall Law Firm before December 15, 2025, to discuss their rights and potential involvement.

Background of the Case

The complaint alleges that MoonLake made numerous false and misleading statements regarding its drug candidate, sonelokimab (SLK), which the company touted as being superior to other monoclonal antibodies. Despite these claims, internal information suggested that the drug had no proven advantages over its competitors. After announcing disappointing results from a Phase 3 trial, which led analysts to label the findings as "disastrous," MoonLake's stock plummeted, losing nearly 90% of its value.

Following this dramatic market shift, affected investors have been urged to take action. For those who sustained losses during this Class Period, this lawsuit provides a potential avenue for recovery through collective legal action.

How to Participate

Investors wishing to pursue their legal rights can reach out to Brian Schall, the lead attorney at the Schall Law Firm, either by phone at 310-301-3335 or through the firm's website. Participation in the lawsuit is free of charge until the class is officially certified. If investors choose to remain passive and do not participate, they will fall into the category of absent class members and may miss the opportunity to recover their investment losses.

Implications for the Market

This case stands as a broader reminder of the responsibility companies have in providing accurate information to their investors. Misleading statements not only damage investor trust but can also result in severe financial repercussions for shareholders when the truth comes to light. The Schall Law Firm specializes in representing investors globally in cases of securities class actions and shareholder rights litigation. Their commitment to advocating on behalf of harmed investors underscores the importance of transparency within the financial markets.

Conclusion

MoonLake Immunotherapeutics is currently facing significant scrutiny over its handling of public statements regarding its drug candidates. As the lawsuit unfolds, investors who believe they were misled about the company's prospects may find solace in joining this class action. The deadline for involvement is approaching, providing a limited window for action. Thus, affected investors should assess their potential claims by reaching out to legal counsel promptly. This case is emblematic of the ongoing challenges in the healthcare sector, where the stakes are high, and the ramifications of failed expectations can be devastating. Investors are encouraged to remain vigilant and aware of their rights as shareholders.